Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats

BACKGROUND: Avitinib is one type of the third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer (NSCLC) with EGFR mutations. The purpose of this study was to investigate the effect of avitinib on the pharmacokinetics...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Thorac Cancer
Asıl Yazarlar: Wu, Qingjun, Jiang, Hui, Wang, Shuanghu, Dai, Dapeng, Chen, Feifei, Meng, Deru, Geng, Peiwu, Tong, Hongfeng, Zhou, Yunfang, Pan, Debiao, Zhou, Quan, Wang, Chunjie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons Australia, Ltd 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7529555/
https://ncbi.nlm.nih.gov/pubmed/32812378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13587
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller